|13.66||-0.1500||-1.09%||Vol 35.99K||1Y Perf 23.30%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||23.33||Analyst Rating||Strong Buy 1.00|
|Potential %||70.79||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||54.36||Earnings Rating||—|
|Market Cap||299.54M||Earnings Date||8th Nov 2023|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Nov 2023|
|Estimated EPS Next Report||-0.80|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||141.85K|
|Avg. Monthly Volume||83.41K|
|Avg. Quarterly Volume||99.57K|
AN2 Therapeutics Inc. (NASDAQ: ANTX) stock closed at 13.66 per share at the end of the most recent trading day (a -1.09% change compared to the prior day closing price) with a volume of 35.99K shares and market capitalization of 299.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. AN2 Therapeutics Inc. CEO is .
The one-year performance of AN2 Therapeutics Inc. stock is 23.3%, while year-to-date (YTD) performance is 43.34%. ANTX stock has a five-year performance of %. Its 52-week range is between 4.87 and 21.0399, which gives ANTX stock a 52-week price range ratio of 54.36%
AN2 Therapeutics Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 1.86, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.81%, a ROC of -32.79% and a ROE of -32.10%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AN2 Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.80 for the next earnings report. AN2 Therapeutics Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for AN2 Therapeutics Inc. is Strong Buy (1), with a target price of $23.33, which is +70.79% compared to the current price. The earnings rating for AN2 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AN2 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AN2 Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.98, ATR14 : 1.11, CCI20 : -115.36, Chaikin Money Flow : 0.00, MACD : 0.59, Money Flow Index : 32.51, ROC : -14.63, RSI : 51.26, STOCH (14,3) : 24.71, STOCH RSI : 0.28, UO : 37.95, Williams %R : -75.29), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AN2 Therapeutics Inc. in the last 12-months were: Capital Management, L.P. Ra (Buy at a value of $16 000 002), Eric Easom (Buy at a value of $53 800), Eric Easom (Sold 87 392 shares of value $1 391 311 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.